Hepatitis B virus infection in the dialysis population: Current perspectives

International Journal of Artificial Organs

Volumn 31, Issue 5, 2008, Pages 386-394

  Fabrizi, Fabrizio ^a   Marzano, A ^b   Messa, P ^a   Martin, P ^c   Lampertico, P ^d  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Dialysis; Hepatitis B virus (HBV); Interferon; Lamivudine

Indexed keywords

ANTIBIOTICS; CLINICAL RESEARCH; DEVELOPING COUNTRIES; DIAGNOSIS; DIALYSIS; GLYCOPROTEINS; PATIENT MONITORING; PATIENT TREATMENT; POPULATION STATISTICS;

'CURRENT; CHRONIC CARRIERS; HEPATITIS B VIRUS; HEPATITIS B VIRUS INFECTION; INTERFERON; LAMIVUDINE; LIMITED DATA; NATURAL HISTORY; VIRAL LOAD;

VIRUSES;

ADEFOVIR; ALPHA INTERFERON; LAMIVUDINE; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; COMORBIDITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EPIDEMIC; HEMODIALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY FAILURE; PREVALENCE; REVIEW; SCREENING TEST; SERODIAGNOSIS; VIRUS CARRIER; VIRUS DETECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 47249166034     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880803100503     Document Type: Review

References (69)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089.
2. Finelli L, Miller JT, Tokars JI, Altar MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18: 52-61.
3. Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, Saito A, La Bracque J, Port FK, Young EW. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOO-PS. Kidney Int 2003; 63: 2222-9.
4. Inoue K, Ogawa O, Yamada M, Watanabe T, Okamoto H, Yoshiba M. Possible association of vigorous hepatitis B virus replication with the development of fulminant hepatitis. J Gastroenterol 2006; 41: 383-7.
5. Kondili LA, Genovese D, Argentini C, Chionne P, Toscani P, Fabro R, Cocconi R, Rapicetta M. Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a haemodialysis center. Eur J Clin Microbiol Infect Dis 2006; 25: 527-31.
6. Ferreira RC, Teles SA, Dias MA, Tavares VR, Silva SA, Gomes SA, Yishida CF, Martins RM. Hepatitis B virus profile in hemodialysis patients in Central Brazil: prevalence, risk factors, and genotypes. Mem Inst Oswaldo Cruz 2006; 101: 689-92.
7. Chandra M, Khaja MN, Hussain MM, Posuri CD, Farees N, Habeeb MA, Krishnan S, Ramareddy GV, Habibullah CM. Prevalence of hepatitis B and hepatitis C viral infections in Indian patients with chronic renal failure. Intervirology 2004; 47: 374-6.
8. Souza KP, Luz JA, Teles SA, Carneiro MA, Oliveira LA, Gomes AS, Dias MA, Gomes SA, Yoshida CF, Martins RM. Hepatitis B and C in the hemodialysis unit of Tocantins, Brazil: Serological and molecular profiles. Mem Inst Oswaldo Cruz 2003; 98: 599-603.
9. Busek SU, Baba EH, Tavares Filho HA, Pimenta L, Salomao A, Correa-Oliveira R, Oliveira GC. Hepatitis C and hepatitis B virus infection in different hemodialysis units in Belo Horizonte, Minas Gerais, Brazil. Mem Inst Oswaldo Cruz 2002; 97: 775-8.
10. Qadi AA, Tamim H, Ameen G, Bu-Ali A, Al-Arrayed S, Fawaz NA, Almawi WY. Hepatitis B and hepatitis C virus prevalence among dialysis patients in Bahrain and Saudi Arabia: A survey by serologic and molecular methods. Am J Infect Control 2004; 32: 493-5.
11. Chattopadhyay S, Rao S, Das BC, Singh NP, Kar P. Prevalence of transfusion-transmitted virus infection in patients on maintenance hemodialysis from New Delhi, India. Hemodial Int 2005; 9: 362-6.
12. Carrilho FJ, Moraes CR, Pinho JRR, Mello IMVGC, Bertolini DA, Lemos MF, Moreira RC, Bassit LC, Cardoso RA, Ribeirodos-Santos G, Da Silva LC. Hepatitis B virus infection in haemodialysis centres from Santa Catarina State, Southern Brazil. Predictive risk factors for infection and molecular epidemiology. BMC Public Health 2004; 4: 13-24.
13. Yakaryilmaz F, Gurbuz OA, Guliter S, Mert A, Songur Y, Karakan T, Keles H. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren Fail 2006; 28: 729-35.
14. Marcelli D, Stanhard D, Conte F, Held PJ, Locatelli F, Port FK. ESRD patients mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int 1996; 50: 1013-8.
15. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, Caraceni P, Daniele B, Di Marco V, Fabrizi F, Fagiuoli S, Grossi P, Lampertico P, Meliconi R, Mangia A, Puoti M, Raimondo G, Smedile A, for the Italian Association for the Study of the Liver (AISF). Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.
16. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredkie M, Boyle P. Cancer in patients on dialysis for end-stage renal disease: an international and collaborative study. Lancet 1999; 354: 93-9.
17. Josselson J, Kyser BA, Weir MR, Sadler JH. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. Am J Kidney Dis 1987; 6: 456-61.
18. Jha R, Kher BA, Naik S, Elhance R, Gupta A, Sharma RK. Hepatitis B associated liver disease in dialysis patients: role of vaccination. J Nephrol 1993; 6: 98-103.
19. Yasuda K, Okuda K, Endo N, Ishiwatari Y, Ikeda R, Hayashi H, Yokozeki K, Kobayashi S, Irie Y. Hypoaminotransferasemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Gastroenterology 1995; 109: 1295-1300.
20. Guh JY, Lai YH, Yang CY, Chen SC, Chuang WL, Hsu TC, Chen HC, Chang WY, Tsai JH. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995; 69: 459-65.
21. Fabrizi F, Lunghi G, Colucci P, Finazzi S, Ponticelli C, Locatelli F. Reduced aminotransferase activity in patients with chronic renal failure not requiring dialysis: Impact on the evaluation of viral hepatitis. Am J Kidney Dis 2001; 28: 1009-15.
22. Espinosa E, Martin-Malo A, Alvarez de Lara MA, Soriano S, Alijama P. High ALT levels predict viremia in anti HCV positive HD patients if a modified normal range of ALT us supplied. Clin Nephrol 2000; 54: 151-6.
23. Fabrizi F, Mangano S, Alongi G, Bisegna S, Finazzi S, Lunghi G, Ponticelli C. Influence of HBV viremia upon aminotransferase activity in the dialysis population. Int J Artif Organs 2003; 26: 1048-55.
24. Fabrizi F, De Vecchi AF, Qureshi AR, Aucella F, Lunghi G, Bruchfeld A, Bisegna S, Mangano S, Limido A, Vigilante D, Forcella M, Delli Carri P, Martin P. Gammaglutamyltranspeptidase activity and viral hepatitis in dialysis patients. Int J Artif Organs 2007; 30: 6-15.
25. Fabrizi F, Lunghi G, Alongi G, Bisegna S, Campolo G, Mangano S, Limido A, Pagliari B, Tettamanzi F, Ponticelli C. Biological dynamics of hepatitis B virus load in the dialysis population. Am J Kidney Dis 2003; 41: 1278-85.
26. Moutinho RS, Perez RM, Median-Pestana JO, Figueredo MS, Koide S, Lopes Alberto F, Silva AEB, Ferraz MLG. Low HBV DNA levels in end-stage renal disease patients with HBeAg-negative chronic hepatitis B. J Med Virol 2006; 78: 1284-8.
27. Kohler H. Hepatitis B immunization in dialysis patients- is it worthwhile? Nephrol Dial Transplant 1994; 9: 1719-20.
28. Salo JR, Salo AA, Fahlberg WJ, Ellzey JT. Hepatitis B surface antigen in peritoneal fluid of HBsAg carriers undergoing peritoneal dialysis. J Med Virol 1980; 6: 29-35.
29. Kroes ACM, van Bommel EFH, Niesters HGM, Weimar W. Hepatitis B viral DNA detectable in dialysate. Nephron 1994; 67: 369.
30. Moynot A, Lazizi Y, Dubeuil P, Buisson C, Pillot J. Nature of HBsAg ultrafiltrate of haemodialysed patients: presence of viral DNA. Nephrol Dial Transplant 1988; 49: 88.
31. de Jong GM, de Bruin W, Verresen L, Moshage H, Desmyter J, Yap SH. High-flux membranes are not permeable to hepatitis B virus DNA. Nephron 1992; 60: 368.
32. Rostaing L, Chatelut E, Payen JL, Izopet J, Thalaamas C, Ton-That H, Pascal JP, Durand D, Canal P. Pharmacokinetics of alpha-2b in chronic hepatitis C undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344-8.
33. Badalamenti S, Catania A, Lunghi G, Covini G, Bredi E, Brancaccio D, Saalvadori M, Como G, Ponticelli C, Graziani G. Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus positive patients only coincidental phenomena? Am J Kidney Dis 2003; 42: 143-50.
34. Fabrizi F, Lunghi G, Alongi G, Aucella F, Barbisoni F, Bisegna S, Corghi E, Faranna P, Mangano S, Romei-Longhena G, Martin P. Kinetics of hepatitis B virus load and hemodialysis: A prospective study. J Viral Hepat (submitted).
35. Noiri E, Nakao A, Oya A, Fujita T, Kimura S. Hepatitis C virus in blood and dialysate in hemodialysis. Am J Kidney Dis 2001; 37: 38-42.
36. Ahuja TS, Niaz N, Velasco A, Watts B, Paar D. Effect of hemodialysis and antiretroviral therapy on plasma viral load in HIV-1 infected hemodialysis patients. Clin Nephrol 1999; 51: 40-4.
37. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, Reveal-HBV Study group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
38. Villeneuve JP, Desrochers M, Infante-Rivard C, Willems B, Raymond G, Bourcier M, Cote J, Richer G. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994; 106: 1000-5.
39. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-70.
40. Larsen J, Hetland G, Skaug K. Posttransfusion hepatitis B transfused by blood from a hepatitis B surface antigen-negative hepatitis B virus carrier. Transfusion 1990; 30: 431-2.
41. Munoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002; 8: S82-7.
42. Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, David MF, Arulnaden JL, Bismuth A, Reynes M, Bismuth H. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997; 26: 517-26.
43. Larghi A, Leffler D, Frucht H, Rubin M, Semrad CE, Lefkowitch JH, Worman HJ. Hepatitis B virus reactivation after kidney transplantation and new onset lymphoma. J Clin Gastroenterol 2003; 36: 276-80.
44. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-9.
45. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, Gerlich WH, Thiel E. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.
46. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004; 127 (Suppl): S56-61.
47. Chemin I, Zoulim F, Merle P, Arkhis A, Chevallier M, Kay A, Cova L, Chevallier P, Mandrand B, Trepo C. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol 2001; 34: 447-54.
48. Zhang YY, Hansson BG, Kuo LS, Widell A, Nordenfelt E. Hepatitis B virus DNA in serum and liver is commonly found in Chinese patients with chronic liver disease despite the presence of antibodies to HBsAg. Hepatology 1993; 17: 538-44.
49. Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, Gutkin A, Bernstein K, Giulivi A, Osiowy C. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology 2004; 40: 1072-7.
50. Besisik F, Karaca C, Akyuz F, Horosauli S, Onel D, Badur S, Sever MS, Danalioglu A, Denir K, Kaymakoglu S, Cakaloglu Y, Okten A. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol 2003; 38: 506-10.
51. Goral V, Ozkul H, Tekes S, Sit D, Kadiroglu K. Prevalence of occult HBV infection in haemodialysis patients with chronic HCV. World J Gastroenterol 2006; 12: 3420-4
52. Fabrizi F, Messa P, Lunghi G, Aucella F, Bisegna S, Mangano S, Villa M, Barbisoni F, Rusconi E, Martin P. Occult hepatitis B virus infection in dialysis patients: a multicentre survey. Aliment Pharmacol Ther 2005; 21: 1341-7.
53. Kanbay M, Gur G, Akcay A, Selcuk H, Yilmaz U, Arslan H, Boyacioglu S, Ozdemir FN. Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients? Digest Dis Sci 2006; 51: 1962-6.
54. Siagris D, Christofidou M, Triga K, Pagoni N, Theocharis GJ, Goumenos D, Lekkou A, Thomopoulos K, Tsamandas AC, Vlachojannis J, Labropoulou-Karatza C. Occult hepatitis B virus infection in hemodialysis patients with chronic HCV infection. J Nephrol 2006; 19: 327-33.
55. Pao CC, Yang WL, Huang CC, Hsu JL, Lin SS, Ken R, Chao Y, Sun CF, Liaw YF, Lin JY. Hepatitis type B virus DNA in patients receiving hemodialysis: correlation with other HBV serological markers. Nephron 1987; 46: 155-60.
56. Cabrerizo M, Bartolome J, De Sequera P, Caramelo C, Carreno V. Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff. J Am Soc Nephrol 1997; 8: 1443-7.
57. CDC. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR 2001 ; 50 (RR-5): 1-41.
58. Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, Reiss P, Thiebaut R, Weiland O, Yazdanpanah Y, Zeuzem S, ECC Jury. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis C and B in HIV co-infected patients. J Hepatol 2005; 42: 615-24.
59. Locarnini S, Hatzakis A, Heathcote J, Keefe EB, Liang TJ, Mutimer D, Pawlotsky JM, Zoulim F. Management of antiviral resistance in patients with chronic hepatitis B. Antiviral Ther 2004; 9: 679-93.
60. Duarte R, Huraib S, Said R, Abdel-Khadir A, Sullivan S, Chaballout A, Sbeih F, Mughal T. Interferon-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis. Am J Kidney Dis 1995; 25: 40-5.
61. Giorgianni V, Gattarello G, Cannata L, et al Trattamento con interferone alfa in pazienti emodializzati cronici con epatite cronica. G Ital Nefrol 1992; 9: 221-2.
62. Tillmann HL, Wedmeyer H, Manns PM. Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation. J Hepatol 2003; 39: S206-11.
63. Lapinski TW, Flisiak R, Jaroszewicz J, Michalewicz M, Kowalczuc O. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J Gastroenterol 2005; 11: 400-2.
64. Boyacioglu S, Gur G, Gursoy M, Ozdemir N. Lamivudine in renal transplant candidates with chronic hepatitis B infection. Transplant Proc 2002; 34: 2131-2.
65. Ben-Ari Z, Broida E, Kittai Y, Chagnac A, Tur-Kaspa R. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation. Am J Gastroenterol 2000; 95: 3579-83.
66. Fontaine H, Thiers V, Chretien Y, Zylberberg H, Poupon RE, Brechot C, Legendre C, Kreis H, Pol S. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000; 69: 2090-4.
67. Schmilovitz-Weiss H, Melzer E, Tu-Kaspa R, Ben-Ari Z. Excellent outcome of lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J Clin Gastroenterol 2003; 37: 64-7.
68. Fontaine H, Vallet-Pichard A, Chaix ML, Currie G, Serpaggi J, Verkarre V, Varaut A, Morales E, Nalpas B, Bosgart C, Pol S. Efficacy and safery of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005; 80: 1086-92.
69. Tillmann HL, Bock CT, Black JS, Rosenau J, Baker KH, Bong-Hock H, Becker T, Trautwein C, Klenpnauer J, Flemming P, Manns P. Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. Liver Transpl 2003; 9: 191-96.